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Background How body size influences risk of molecular subtypes of colorectal
cancer (CRC) is unclear. We investigated whether measures of an-
thropometry differentially influence risk of tumours according to
BRAF c.1799T4A p.V600E mutation (BRAF) and microsatellite in-
stability (MSI) status.
Methods Data from The Netherlands Cohort Study (n¼ 120 852) and
Melbourne Collaborative Cohort Study (n¼ 40 514) were pooled
and included 734 and 717 colorectal cancer cases from each
study, respectively. Hazard ratios (HRs) and 95% confidence inter-
vals (CIs) for body mass index (BMI), waist measurement and
height were calculated and compared for subtypes defined by
BRAF mutation and MSI status, measured from archival tissue.
Results Results were consistent between studies. When pooled, BMI mod-
elled in 5 kg/m2 increments was positively associated with BRAF
wild-type (HR: 1.16, 95% CI: 1.08–1.26) and MS-stable tumours
(HR: 1.15, 95% CI: 1.06–1.24). Waist measurement was also asso-
ciated with BRAF wild-type (highest vs lowest quartile, HR: 1.59,
95% CI: 1.33–1.90) and MS-stable tumours (highest vs lowest quar-
tile HR: 1.68, 95% CI: 1.31–2.15). The HRs for BRAF mutation tu-
mours and MSI tumours were smaller and non-significant, but
differences between the HRs by tumour subtypes were not signifi-
cant. Height, modelled per 5-cm increase, was positively associated
with BRAF wild-type and BRAF mutation tumours, but the HR was
greater for tumours with a BRAF mutation than BRAF wild-type
(HR: 1.23, 95% CI: 1.11–1.37, Pheterogeneity¼ 0.03). Similar associ-
ations were observed with respect to height and MSI tumours
(HR: 1.26, 95% CI: 1.13–1.40, Pheterogeneity¼ 0.02).
Published by Oxford University Press on behalf of the International Epidemiological Association
 The Author 2012; all rights reserved. Advance Access publication 24 April 2012
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Conclusions Generally, overweight increases the risk of CRC. Taller individuals
have an increased risk of developing a tumour with a BRAF muta-
tion or MSI.
Keywords Colorectal neoplasms, BRAF, microsatellite instability, body mass
index, waist circumference, height, cohort study
Introduction
Although it is well documented that body size influ-
ences colorectal cancer (CRC) risk,1 how this risk dif-
fers according to molecular phenotype of tumours is
less clear. Elucidating such differences may lead to a
better understanding of CRC aetiology and
prevention.
One well-defined subgroup of CRC arises through
the (sessile) serrated pathway, via serrated epithelium
or hyperplastic polyps.2 A number of genetic and epi-
genetic abnormalities contribute to the resulting ad-
enoma/carcinoma. The somatic mutation of the BRAF
c.1799T4A p.V600E (BRAF) proto-oncogene is thought
to occur early in disease progression.3 Microsatellite
instability (MSI), which occurs when short, repetitive
DNA sequences undergo an increase or decrease in
repeat length,4 is thought to occur later in the path-
way.2 In sporadic CRC, MSI almost always arises
through loss of function in the mismatch repair
gene MLH1, resulting from promoter methylation.2
An underlying abnormality of tumours harbouring a
BRAF mutation and/or MSI is the CpG island methy-
lator phenotype (CIMP),2 which is characterized by
numerous promoter CpG island hypermethylated
tumour suppressor and DNA repair genes.5–9 This in
turn is associated with transcriptional silencing of
gene expression.10
Ogino et al.11,12 recently described an emerging field
of science now referred to as molecular pathological
epidemiology. This is the integration of molecular
pathology and epidemiology in order to gain insight
into potential mechanisms of disease aetiology and to
analyse environmental risk factors and disease trends
in large numbers of unselected cases. Only a handful
studies have investigated the association between
body size and characteristics of the (sessile) serrated
pathway, and the majority of those was case–control
in design and only considered body mass index (BMI)
as a risk factor.4,13–17 Central adiposity is thought to
be a better predictor of CRC than BMI18 and height
reflects early-life environmental and hormonal expos-
ures,1 therefore, investigating these risk factors in
addition to BMI is warranted.
The Netherlands Cohort Study (NLCS) and the
Melbourne Collaborative Cohort Study (MCCS) are
prospective cohorts in which colorectal tumour
tissue samples have been collected and subse-
quently analysed for molecular characteristics. We
pooled data from individual participants from the
two studies to produce a more accurate estimate of
relative risk.19,20 The purpose of the present study
was to investigate if body size (BMI, indicators of
central adiposity and height) differentially influence
risk of tumours according to BRAF mutation and MSI
status.
Materials and Methods
Study populations and design
NLCS
The NLCS was initiated in 1986 to investigate the
association between diet and the development of
cancer. It includes 58 279 men and 62 573 women
aged 55–69 years at baseline who completed a self-
administered food frequency questionnaire involving
150 food items as well as questions on dietary habits,
lifestyle, health and demographics.21,22 Municipal
registries from throughout The Netherlands were
used to constitute an efficient sampling frame.21–23
The NLCS uses a case–cohort approach for data pro-
cessing and analysis; case subjects were derived from
the entire cohort and the number of person-years at
risk for the entire cohort was estimated from a
subcohort of 5000 men and women who were ran-
domly sampled from the full cohort at baseline. All
subcohort members who reported prevalent cancer
(excluding skin cancer) at baseline were excluded
from analyses, leaving 4654. Further details of the
NLCS design have been described.21–23
Incident CRC cases were identified by annual record
linkage to nine regional cancer registries and a
national pathology database (PALGA).24 The com-
pleteness of cancer follow-up is almost 100%.25
Paraffin-embedded tumour material from CRC pa-
tients was retrieved, as described previously.26 In
total, 734 incident CRC patients were identified from
a follow-up period of 7.3 years after baseline (until
December 31, 1993), excluding the first 2 years of
follow-up, of whom a PALGA report of the lesion as
well as sufficient DNA were available.26
The study protocol was approved by the Medical
Ethics Committees of the University Hospital
Maastricht and TNO Nutrition. Tumour material was
collected after approval by the ethical review boards
of Maastricht University, the National Cancer Registry
and PALGA.
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MCCS
The MCCS is a prospective cohort study of 17 045 men
and 24 469 women, who were between the age of 27
and 75 years at recruitment from 1990 to 1994
(almost all were aged 40–69 years), and includes
5425 migrants from Italy and 4535 from Greece. For
this analysis, 202 participants who had a CRC diag-
nosed before baseline were excluded, leaving a total
of 41 312 individuals. Subjects were recruited via the
electoral rolls (registration to vote is compulsory for
adults in Australia), advertisements and community
announcements in local media (e.g. television, radio
and newspapers). Comprehensive lists of Italian and
Greek surnames were also used to target Southern
European migrants listed in the phone books and
on electoral rolls. A structured interview schedule
was used to obtain information on potential risk fac-
tors. Information on current diet was obtained from a
dietary questionnaire that contained a 121-item food
frequency questionnaire that was developed for the
MCCS.27
Cases were participants who had a first diagnosis of
invasive cancer of the colon or rectum during
follow-up to December 31, 2004, identified by linkage
to population-based cancer registries in all Australian
states. Addresses and vital status of the subjects were
determined by record linkage to electoral rolls, the
National Death Index, Victorian death records, from
electronic phone books and from responses to mailed
questionnaires and newsletters. Archival tumour
tissue was sought for all primary, histopathologically
confirmed adenocarcinomas diagnosed in Victoria. In
the MCCS, 717 tumours were available for analysis.
The study protocol was approved by the Cancer
Council Victoria’s Human Research Ethics
Committee. Participants gave written consent for par-




Height (cm) and body weight (kg) were self-reported
on the baseline questionnaire. BMI was subsequently
calculated. At baseline, individuals were also asked to
report their lower body (trouser or skirt) clothing size
from their clothing label (Dutch sizes). Clothing size
appears to predict cancer risk independently of BMI
and corresponds to waist measurements.28
MCCS
Height (cm), weight (kg) and waist circumference
(cm) were measured at baseline attendance for each
participant according to written protocols that were
based on standard procedures.29 Weight was mea-
sured to 100 g using digital electronic scales, height
to 1 mm using a stadiometer and waist circumference
was measured to 1 mm using a 2 -m metal anthropo-
metric tape. BMI was calculated from weight and
height.
Molecular pathology
Although CIMP has been measured in both studies, it
was not considered here because different methods of
measurement were used, leading to different propor-
tions of CRC s showing the phenotype.
NLCS
BRAF mutation analysis was done by a semi-nested
PCR and subsequent restriction fragment length poly-
morphism (RFLP) analyses as previously described.30
MSI was determined by a pentaplex PCR using the
MSI markers BAT-26, BAT-25, NR-21, NR-22 and
NR-24, as described in detail by Suraweera et al.31
Tumours were classified as MSI-high if two or more
markers showed instability and as MSI-low/MS-stable
(MSS) if one or none of the markers examined
showed instability.
MCCS
BRAF mutation analysis was done by a real-time
PCR-based allelic discrimination method.32 MSI was
examined using 10 microsatellite markers.33 High-
frequency MSI (MSI-H) was defined as 430% in-
stability of at least five markers; low-level MSI
(MSI-L) was defined as 1–29% of loci unstable.
Tumours were classified as MSI-high, MSI-intermedi-
ate, MSI-low and MS-stable, but for comparability
with the NLCS, MSI-low and MS-stable were com-
bined into one category.
In both NLCS and MCCS, cases with and without
tumour tissue retrieved were similar with respect to
established risk factors for CRC, indicating that no
selection bias was introduced as a result of inability
to retrieval tissue for all cases.
Statistical analyses
Data were analysed with Stata (version 10, Statacorp,
College Station, TX, USA). Hazard ratios (HRs), 95%
confidence intervals (95% CIs) and P-values were cal-
culated using Cox regression with age as the time-
scale.34 To account for its case–cohort design,
survival times in the NLCS were adapted using
Prentice weights.35
To estimate HRs separately for different molecular
subtypes and to test their difference (i.e. BRAF muta-
tion vs BRAF wild-type), Cox models based on com-
peting risks were fitted using a data duplication
method.36 Person-years of follow-up were calculated
from baseline until the date of CRC diagnosis, death
or end of follow-up.
Study-specific analyses
BMI (per 5 kg/m2) and height (per 5 cm) were fitted
as continuous covariates to estimate linear trends on
the log hazard scale and as categorical variables.
These variables were additionally considered as sex-
and study-specific quartiles. With respect to waist
measurements, trouser/skirt size and waist
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circumference were fitted categorically for NLCS and
MCCS data, respectively, according to approximate
sex-specific quartiles. All models were stratified by
sex and the MCCS was additionally stratified by eth-
nicity (based on country of birth and classified into
two groups: Southern European (born in Italy or
Greece) and Anglo-Celtic (born in Australia, New
Zealand, UK or Ireland).37
Several potential confounding variables were con-
sidered for multivariate analysis. For the NLCS,
these included family history of CRC (yes/no), smok-
ing status (never smoker, ex-smoker and current
smoker), education (primary school, junior high
school, senior high school, higher vocational school
or university), total energy intake (kcal/day), alcohol
intake (0, 0.1–4, 5–14, 15–29 and 530 g/day), recre-
ational physical activity (<30, 30–60, 61–90 and
490 min/day) and consumption of red meat, fruit,
vegetables, fibre and grains (g/day). For women, hor-
monal factors such as contraceptive use (yes/no), HRT
use, age at menarche, age at menopause and number
of children were also tested. For the MCCS, the vari-
ables considered were smoking status (current
smoker, former smoker and never smoker), education
(primary school, some high/technical school, com-
pleted high school and completed tertiary degree/ dip-
loma), total dietary energy intake (kcal/day), current
alcohol consumption (males 0, 1–39 and 540 g/day;
females 0, 1–19 and 520 g/day), current level of phys-
ical activity (none, low, moderate and high), meat,
fruit and vegetable (servings/day) intake, fibre from
cereal products, multivitamin and fibre supplements
(yes/no). For women, parity, total months of lactation
for all live births, age at first live birth, age at menar-
che, HRT use (never, former and current), oral contra-
ceptive pill usage (never and ever), menopausal status
and age at menopause were also considered. In the
respective studies, no variables changed the estimated
HRs by410% and therefore none was included in the
final models.
Pooled analyses
Models were stratified by study, ethnicity and sex.
HRs, 95% CIs and P-values were estimated for a
5-kg/m2 increase in BMI and a 5-cm increase in
height. Waist measurement was not considered con-
tinuously for the pooled data, because of differences
in measurement. BMI, waist measurement and height
were additionally considered according to sex and
study-specific quartiles. The NLCS was coded to re-
flect a non-Southern European ethnicity. Due to the
increase in sample size, sex-specific analyses were also
conducted.
Tests based on Schoenfeld residuals and graphical
methods using Kaplan–Meier curves showed no evi-
dence that proportional hazard assumptions were vio-
lated for any analyses.
Results
Generally, men and women in the NLCS were older,
taller and had a lower BMI than those in the MCCS.
There was a higher proportion of current and
ex-smokers in the NLCS than in the MCCS
(Tables 1 and 2).
Of the 734 incident tumours in the NLCS, 697 were
successfully analysed for BRAF p.V600E c.1799T4A
mutation status and 658 for MSI (Table 3). Of the
717 tumours identified in the MCCS, BRAF mutation
status was determined for 582 and MSI status for
585. Further details of the cancers in each cohort
are in previous publications.37–40 For both studies,
16% of the cancers evaluated had BRAF mutations.
In the NLCS, 14% of tumours from males and 19%
from females had BRAF mutations, whereas in the
MCCS, the proportions were 11 and 19%, respectively.
Cases with BRAF mutation tended to be older and
taller than non-BRAF cases. With respect to MSI
status, 13% of the cancers evaluated in the NLCS
and 15% in the MCCS were MSI high. In the NLCS,
12% of the tumours from males and 14% from fe-
males were MSI, whereas in the MCCS, the propor-
tions were 12 and 18%, respectively. MSI-high cases
tended to be taller than MSS cases
Associations between body size and CRC risk ac-
cording to BRAF status are shown in Table 4. For
both studies, BMI modelled per 5-kg/m2 increase
was associated with BRAF wild-type tumours (NLCS
HR: 1.28/5 kg/m2, 95% CI: 1.12–1.45; MCCS HR: 1.10,
95% CI: 0.99–1.21). This association remained when
the data were pooled (HR: 1.16, 95% CI: 1.08–1.26).
After pooling and considering BMI in sex and study-
specific quartiles, there was a positive dose–response
association only for BRAF wild-type tumours and no
association with respect to tumours with a BRAF mu-
tation. Tests for heterogeneity between BRAF subtypes
were not statistically significant.
With respect to waist measurements in the MCCS,
there were similar dose–response associations for both
BRAF-mutated and BRAF wild-type tumours when
considering quartiles of waist circumference; however,
these only reached statistical significance for the
BRAF wild-type group. This was also observed in the
NLCS for clothing size, although there was less evi-
dence of a dose–response. When the data were
pooled, there was a statistically significant positive
dose–response association for BRAF wild-type
tumours (highest vs lowest quartile HR: 1.59, 95%
CI: 1.33–1.90 and P trend < 0.001). A statistically sig-
nificant trend was also observed for BRAF-mutated
tumours (P¼ 0.03).
When height was modelled per 5-cm increment,
there was an increased risk for both tumours with
and without BRAF mutations, although the HR was
greater for BRAF-mutated tumours. For the pooled
data, the HR for tumours with BRAF mutations was
1.23/5-cm increment (95% CI: 1.11–1.37) compared
with 1.08 (95% CI: 1.03–1.13) for tumours without
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Table 1 Baseline demographic, anthropometric, dietary and lifestyle characteristics of NLCS
Characteristics Males Females
Total in cohort 58 279 62 573
Total in subcohorta 2232 2399
Age (years)b 61.3 (4.2) 61.5 (4.3)
Weight (kg) 77.8 (9.5) 68.5 (10.3)
Height (cm) 176.4 (6.7) 165.1 (6.3)
BMI (kg/m2) 25.0 (2.6) 25.1 (3.6)












Primary school 27 35
Some high school 21 23
Completed high school 34 33
Completed tertiary school 18 8
Family history of CRC (%)
No 95 94
Yes 5 6
Recreational physical activity (%)




Total energy (kcal/day) 2148 (526) 1655 (417)
Red meat (g/day) 104.8 (44.2) 92.3 (41.2)
Fibre (g/day) 28.4 (9.0) 24.9 (7.3)





aThe NLCS uses a case–cohort approach for data processing and estimating person-time at risk for the entire cohort. This subcohort
consists of 5000 individuals, of whom 4631 were available for the present analysis.
bMean (SD) or percentages where indicated.
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Table 2 Baseline demographic, anthropometric, dietary and lifestyle characteristics of the MCCS
Characteristics Males Females
Total in cohort 16 942 24 370
Age (years)a 55.8 (8.8) 55.0 (8.6)
Weight (kg) 80.8 (11.8) 68.2 (12.4)
Height (cm) 172.4 (7.4) 159.8 (6.7)
BMI (kg/m2) 27.2 (3.6) 26.7 (4.9)






Lifetime abstainer 14 39
Ex-drinker 5 3
Low intake 27 19
Medium intake 29 21
High intake 25 17
Education (%)
Primary school 19 20
Some high school 31 43
Completed high school 25 18
Completed tertiary school 25 19











Fibre (g/day) 32.2 (12.7) 30.0 (11.2)
Folate (mg/day) 330.2 (149.0) 321.3 (143.9)




aMean (SD) or percentages where indicated.
bSex-specific categorization.
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Table 3 Characteristics of participants in the NLCS and MCCS by CRC status
Characteristics
CRC diagnosed during follow-up
No cancer
BRAF V600E mutation status MSI status
Mutation Wild-type MSI-high MSI-stable
NLCS
Total (%) 4631a 112 (16)b 585 (84) 84 (13) 574 (87)
Sex (%)
Male 48 47 57 50 55
Female 52 53 43 50 45
Age (years)c 61.4 (4.2) 62.8 (4.1) 63.0 (4.1) 62.9 (4.0) 63.5 (4.5)
Height (cm)
Male 176.4 (6.7) 177.8 (7.9) 176.6 (6.6) 177.0 (7.3) 176.9 (6.8)
Female 165.1 (6.2) 166.5 (5.3) 166.0 (6.6) 167.2 (5.3) 166.1 (6.6)
BMI (kg/m2) 25.1 (3.1) 25.4 (2.9) 25.6 (3.2) 25.6 (3.3) 25.5 (3.1)
Clothing size
Male 51 (4) 52 (4) 52 (4) 52 (2) 52 (3)
Female 44 (3) 44 (3) 44(3) 44 (3) 44 (3)
MCCS
Total (%) 40 595 95 (16) 487 (84) 90 (15) 495 (85)
Sex (%)
Male 41 35 53 40 52
Female 59 65 47 60 48
Age (years) 55.2 (8.7) 62.4 (6.4) 60.4 (7.4) 60.4 (7.9) 60.7 (7.3)
Height (cm)
Male 172.4 (7.4) 173.8 (6.5) 171.8 (7.0) 176.1 (5.9) 171.4 (6.9)
Female 159.8 (6.7) 161.4 (6.6) 159.4 (6.7) 159.7 (6.0) 159.9 (7.0)
BMI (kg/m2) 26.9 (4.4) 26.8 (4.3) 27.5 (4.1) 26.9 (4.1) 27.5 (4.2)
Waist circumference (cm)
Male 93.4 (10.0) 95.6 (9.5) 96.2 (9.4) 94.1 (8.9) 96.5 (9.4)
Female 79.9 (11.8) 82.7 (11.8) 82.6 (12.3) 83.1 (11.0) 82.6 (12.5)
Pooled data
Total (%) 45 226 207 (16) 1072 (84) 174 (14) 1069 (86)
Sex (%)
Male 42 42 55 45 54
Female 58 58 45 55 46
Age 55.8 (8.5) 62.6 (5.2) 61.8 (6.0) 61.9 (6.7) 61.9 (5.9)
Height
Male 172.9 (7.4) 176.3 (7.6) 174.5 (7.2) 176.6 (6.7) 174.4 (7.3)
Female 160.3 (6.8) 163.8 (6.5) 162.8 (7.4) 162.9 (6.8) 163.0 (7.4)
BMI 26.7 (4.4) 26.0 (3.7) 26.5 (3.8) 26.3 (3.7) 26.4 (3.8)
Site (%)
Proximal colon – 62 27 74 27
Distal colon – 17 31 13 30
Rectosigmoid/rectum – 18 39 9 40
Unknown – 2 3 4 3
MSI status (%)
MSI-stable – 57 92 – –
MSI-high – 43 8 – –
aSubcohort derived from total cohort to estimate person-time at risk.
bN (%).
cMean (SD) or percentages where indicated.
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BRAF mutations (Pheterogeneity¼ 0.03). Height was also
associated with both tumour subtypes when modelled
according to sex- and study-specific quartiles, show-
ing a positive dose–response association that was
stronger for mutated than wild-type tumours.
Table 5 shows associations according to MSI status.
HRs for pooled BMI and waist measurements were
similar to those observed for BRAF; a statistically sig-
nificant association was observed only for MSS
tumours. Height was also associated with both
tumour subtypes. For the pooled data, the HR for
MSI-high tumours was 1.26/5 cm increase (95% CI:
1.13–1.40) compared with 1.08 (95% CI: 1.03–1.14)
for MSS tumours (P heterogeneity¼ 0.02).
Stratifying the analyses according to sex showed no
differences between men and women.
Discussion
We present prospective cohort data on associations
between body size and molecular subsets of CRC, spe-
cifically BRAF mutation and MSI status. We pooled
data from the NLCS and MCCS and observed that
there was little heterogeneity between tumour sub-
types when considering associations according to
BMI and waist measurement; however, BMI and
waist measurements were strong risk factors for
tumours without BRAF mutations or MSI.
Interestingly, associations with height showed more
heterogeneity; our findings suggest that height is a
stronger risk factor for tumours with BRAF mutations
or MSI.
This is the first molecular pathological epidemiology
study to use pooled data from demographically and
operationally diverse cohorts. Both the NLCS and
MCCS have almost complete ascertainment of CRC
and little loss to follow-up. In the MCCS, body size
at baseline was measured according to standard
protocols. Measures of body size in the NLCS were
obtained by self-report; however, there are many ex-
amples in the literature showing that this method is a
valid and reliable tool for assessing body weight and
height in cohort studies.41–44 As BRAF-mutated
tumours and MSI are uncommon, pooling the NLCS
and MCCS allows for greater precision than in the
individual studies. Meta-analysis is also a strategy
that may be considered when combining the data of
studies. With a meta-analysis, analysis can be per-
formed independently at two sites and is therefore
more economical and easier to perform than pooling
of data. However, an important additional feature of a
pooled analysis is that it is carried out on individual
data. This means that comparability between two stu-
dies can be increased, as study subjects can be reclas-
sified with respect to exposure, outcome and
confounders.45 A case study comparing the outcome
of the two approaches suggests that although the
approaches differ in the statistical analysis,
conclusions reached from meta-analysis and pooled
analysis are broadly consistent.45
To our knowledge, only one study has investigated
the association between BMI and BRAF status in CRC
tumours. In a case–control study, Slattery et al.14 re-
ported that obesity (BMI 530 kg/m2) was not asso-
ciated with BRAF-mutated tumours (associations with
BRAF wild-type tumours were not reported). Central
adiposity has been identified as a stronger predictor of
CRC than BMI1,18 and based on our observations, we
propose that waist measurements may be a better
predictor of CRC than BMI when analysing data ac-
cording to molecular subtype, especially when there is
limited power to detect associations. Furthermore, it
may reduce heterogeneity between studies. When HRs
were estimated according to waist measurements, the
associations observed in the study-specific analyses
were more comparable with each other than those
observed for BMI and the pooled analysis suggested
a dose–response association with respect to both BRAF
wild-type and MSS tumours. Future studies should
consider this variable in addition to BMI.
Two case–control studies have previously considered
the association between BMI and MSI.4,46 Whereas
the study by Campbell et al.4 distinguished between
MSS and MSI-low tumours, we combined these two
groups because our MSI-low group was very small.
The presence and role of MSI-low remains controver-
sial.47 Mutations often observed in MSI-high tumours
appear to be absent in MSI-low tumours and no large
differences in clinical or molecular characteristics
have been observed between MSS and MSI-low pa-
tients.48 Campbell et al. reported that BMI was asso-
ciated only with MSS and MSI-low tumours, but not
MSI-high tumours. We also observed a positive asso-
ciation between BMI and MSS tumours; however,
tests for heterogeneity between tumour subtypes did
not reach statistical significance in our study. Slattery
et al.46 reported associations according to MSI-positive
(equivalent to MSI high) or MSI-negative (equivalent
to MSS/MSI-low) status, with findings similar to that
of Campbell et al. and additionally reported a positive
association between BMI and MSI-positive tumours
in women. When we performed sex-specific analyses
on the pooled data, we observed no differences be-
tween men and women and no associations with
MSI tumours. Neither case–control study reported as-
sociations according to waist circumference.
A common feature of tumours characterized by
BRAF mutations and MSI is CIMP. Although CIMP
was measured in both studies, it was not considered
here because different methods of measurement were
used, leading to different proportions of CRCs show-
ing the phenotype. This highlights a unique chal-
lenge of pooling molecular data, as well as the fact
that the use of CIMP as an indicator of epigenetic
instability has not been without controversy.49 The
association between body size and CIMP has been
examined in the NLCS cohort.16 Although evidence
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now suggests that CIMP should be discussed within
the context of CIMP-high, CIMP-low and CIMP-
negative tumours,50–52 in the NLCS, associations
were considered according to CIMP-high and CIMP-
negative tumours and those data suggested that a
large body size increases the risk of both subtypes.
This supports the observations reported in the present
article.
Our observations from the pooled data are intri-
guing. For all molecular subtypes considered, we
observed positive associations, which is consistent
with substantial evidence that adult attained height
is a strong risk factor for CRC in general.1 However,
HRs were significantly higher for tumours with BRAF
mutations and MSI than for BRAF wild-type or MSS
tumours, respectively. Height is a marker of an aggre-
gated fetal and childhood experience and can be con-
sidered a proxy measure for important nutritional
exposures, which affect several hormonal and meta-
bolic axes.1 Several studies show that childhood
energy restriction is associated with a decreased risk
of CRC later in life.53–57 Furthermore, we recently re-
ported from the NLCS that exposure to severe energy
restriction during childhood and adolescence was
associated with a low risk of developing a CIMP-posi-
tive tumour.58 Although little research has been done
in this area, our current findings contribute to the
hypothesis that genetic and epigenetic events in CRC
development may be influenced by early-life environ-
mental exposures. This hypothesis may explain why
there was little heterogeneity between tumour sub-
types when considering associations according to
BMI and waist circumferences; these were measured
at baseline in adulthood. Analysing additional cohorts
to draw firmer conclusions is necessary.
Conclusion
In conclusion, our findings reiterate the importance
of a healthy body weight in CRC prevention.
Furthermore, positive associations between height,
BRAF mutation and MSI provide more evidence for
the hypothesis that early life events may influence
genetic and epigenetic mechanisms.
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KEY MESSAGES
 This study shows strengths and weaknesses of pooling molecular pathological epidemiological data.
 We observed that overweight increases the risk of CRC, regardless of the molecular phenotypes
investigated.
 Taller individuals have an increased risk of developing a tumour with a BRAF mutation or MSI.
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